Join
Live feed
·
PRReleasevia Quantisnow
PaxMedica Inc. logo

PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions

ByQuantisnow·Wall Street's wire, on your screen.
PXMD· PaxMedica Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PXMD (PaxMedica Inc.) and more on Quantisnow.